Both the MET and Src tyrosine kinases have been well known as drivers of carcinogenesis and development of resistance to therapies in many cancers including the TNBCs [22–25], and pre-clinical and clinical studies investigating benefits of MET or Src targeting have also been recently reported [26, 27]. Here, MET is linked to cancer.